GSK announces Q2 core EPS growth of 4% and dividend of 18p
- Core EPS growth of 4% on sales growth of 2% (both CER)
- Pharma & Vaccines +1%; US +5%; EMAP +2%; Europe flat; Japan -5%
- Consumer Healthcare +2% (+5% excluding divestments)
- 3 major US approvals: Breo Ellipta for COPD, Tafinlar & Mekinist for metastatic melanoma
- Q2 dividend of 18p (+6%)
- Total share repurchases for 2013 to be £1-2bn
